Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Last trade$1.08
Day change+$0.01 (+0.93%)
Day range$1.01 – $1.15
Volume18,598
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7M
Price / earnings
—
Price / book
7.17×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.74×
Profitability
Earnings per share
-$1.27
Return on assets
-72.69%
Return on equity
-847.9%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.56×
Quick ratio
0.56×
Cash ratio
0.41×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XCUR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$889K
$1.29M
$1.6M
$1.5M
$1.51M
$2.22M
$1.44M
$1.43M
Research and development
$174K
$312K
$655K
$888K
$935K
$808K
$0
$0
Total operating expenses
$1.06M
$1.6M
-$3.72M
$2.39M
$2.45M
-$2.95M
$7.59M
$2.57M
Operating income
-$1.06M
-$1.6M
$3.72M
-$2.39M
-$2.45M
$2.95M
-$7.59M
-$2.57M
Interest expense
$0
$0
-$1K
$0
$0
$0
$0
-$12K
Income before taxes
-$1.12M
-$1.83M
-$3.53M
-$2.44M
-$2.62M
$3.01M
-$7.18M
-$1.08M
Income taxes
$0
$0
-$634K
$0
$0
$0
$0
$8K
Net income
-$1.12M
-$1.83M
-$2.9M
-$2.44M
-$2.62M
$3.01M
-$7.18M
-$1.09M
Net income attributable to common shareholders
-$1.12M
-$1.83M
-$2.9M
-$2.44M
-$2.62M
$3.01M
-$7.18M
-$1.09M
EBITDA
-$1.02M
-$1.55M
-$2.23M
-$2.31M
-$2.38M
-$2.96M
-$1.44M
-$1.43M
Basic earnings per share
-$0.18
-$0.29
-$0.45
-$0.39
-$0.41
$0.49
-$2.55
-$0.57
Diluted earnings per share
-$0.18
-$0.29
-$0.46
-$0.39
-$0.41
$0.49
-$2.55
-$0.57
Recent news
Company coverage with links to the original publishers.
Exicure announced the sale of its GPC-100 (burixafor) program assets to South Korean company GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion). The transaction includes clinical data, intellectual property, and related materials from the Phase 2 clinical trial completed in January 2026. GPCRT will assume future milestone and royalty obligations, while Exicure retains liabilities incurred before September 1, 2026. The sale is part of Exicure's strategic alternatives evaluation to maximize stockholder value.
Exicure, Inc. (Nasdaq: XCUR) received a notification from Nasdaq on May 28, 2026 for non-compliance with listing rules due to delayed filing of its Q1 2026 Form 10-Q. The delay was attributed to changes in financial reporting personnel and procedures. The company filed the report on May 29, 2026 and believes it has regained compliance.
Exicure, Inc. announced a co-development agreement with Korea-based Adbiotech to explore combination therapies using Burixafor (GPC-100) across multiple therapeutic areas including sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech will conduct in vivo studies while Exicure provides Burixafor and leads clinical strategy. The collaboration aims to advance selected programs into IND-enabling studies and clinical trials with future funding to be secured.
Exicure announced publication of Phase 2 data for burixafor, a CXCR4 inhibitor, demonstrating rapid stem cell mobilization in multiple myeloma and lymphoma patients. The study showed 92% of participants met primary endpoints with same-day cell collection capability, significantly faster than currently approved alternatives. The drug was well-tolerated with minimal adverse events and showed potential applications beyond transplant including gene therapy and CAR-T approaches.
Exicure, Inc. announced it will present positive Phase 2 trial data for burixafor at the 2026 Tandem Meetings in Salt Lake City. The trial evaluated burixafor's ability to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous transplantation, with 89.7% of patients meeting the primary endpoint and demonstrating a favorable safety profile with same-day administration.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.